Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023.
- Resource Type
- Academic Journal
- Authors
- Antunes L; Epiconcept, Paris, France.; Mazagatos C; National Centre for Epidemiology, Institute of Health Carlos III, Madrid, Spain.; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.; Martínez-Baz I; Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain.; CIBER Epidemiología y Salud Pública, Madrid, Spain.; Gomez V; Epidemiology Department, National Health Institute Doutor Ricardo Jorge, Lisbon, Portugal.; Borg ML; Infectious Disease Prevention and Control Unit (IDCU), Health Promotion and Disease Prevention, Msida, Malta.; Petrović G; Croatian Institute of Public Health, Zagreb, Croatia.; Duffy R; Health Service Executive-Health Protection Surveillance Centre (HPSC), Dublin, Ireland.; Dufrasne FE; National Influenza Centre Laboratory of Viral Diseases, Sciensano, Brussels, Belgium.; Dürrwald R; National Reference Centre for Influenza, Robert Koch Institute, Berlin, Germany.; Lazar M; Cantacuzino National Military-Medical Institute for Research and Development, Bucharest, Romania.; Jancoriene L; Clinic of Infectious Diseases and Dermatovenerology, Institute of Clinical Medicine, Medical Faculty, Vilnius University, Lithuania.; Oroszi B; National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary.; Husa P; University Hospital Brno, Masaryk University, Brno, Czechia.; Howard J; Epiconcept, Paris, France.; Melo A; Infectious Diseases Department, National Health Institute Doutor Ricardo Jorge, Lisbon, Portugal.; Pozo F; National Centre for Microbiology, Institute of Health Carlos III, Madrid, Spain.; Pérez-Gimeno G; National Centre for Epidemiology, Institute of Health Carlos III, Madrid, Spain.; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.; Castilla J; Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain.; CIBER Epidemiología y Salud Pública, Madrid, Spain.; Machado A; Epidemiology Department, National Health Institute Doutor Ricardo Jorge, Lisbon, Portugal.; Džiugytė A; Infectious Disease Prevention and Control Unit (IDCU), Health Promotion and Disease Prevention, Msida, Malta.; Karabuva S; University Hospital Centre Split, Split, Croatia.; Fitzgerald M; Health Service Executive-Health Protection Surveillance Centre (HPSC), Dublin, Ireland.; Fierens S; Service Epidemiology of Infectious Diseases, Sciensano, Brussels, Belgium.; Tolksdorf K; Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.; Popovici SO; National Institute of Public Health, National Centre for Communicable Diseases Surveillance and Control, Bucharest, Romania.; Mickienė A; Department of Infectious Diseases, Lithuanian University of Health Sciences, Kaunas, Lithuania.; Túri G; National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary.; Součková L; University Hospital Brno, Masaryk University, Brno, Czechia.; Nicolay N; European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.; Rose AM; Epiconcept, Paris, France.
- Source
- Publisher: European Centre for Disease Prevention and Control (ECDC) Country of Publication: Sweden NLM ID: 100887452 Publication Model: Print Cited Medium: Internet ISSN: 1560-7917 (Electronic) Linking ISSN: 1025496X NLM ISO Abbreviation: Euro Surveill Subsets: MEDLINE
- Subject
- Language
- English
We conducted a multicentre hospital-based test-negative case-control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during the Omicron XBB lineage-predominant period in patients aged ≥ 60 years with severe acute respiratory infection from five countries in Europe. Bivalent vaccines provided short-term additional protection compared with those vaccinated > 6 months before the campaign: from 80% (95% CI: 50 to 94) for 14-89 days post-vaccination, 15% (95% CI: -12 to 35) at 90-179 days, and lower to no effect thereafter.